Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
This study has been completed.
Sponsored by: | National Cancer Institute (NCI) Memorial Sloan-Kettering Cancer Center
|
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 6- hydroxymethylacylfulvene in treating patients with metastatic kidney cancer.
Condition | Treatment or Intervention | Phase |
---|---|---|
Stage IV Renal Cell Cancer recurrent renal cell cancer |
Drug: -hydroxymethylacylfulvene |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Kidney Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 6-Hydroxymethylacylfulvene for Advanced Renal Cell Carcinoma
Study start: June 1998
OBJECTIVES: I. Evaluate the efficacy of 6-hydroxymethylacylfulvene (HMAF) in patients with metastatic renal cell carcinoma.
II. Investigate the safety of HMAF given to this patient population.
PROTOCOL OUTLINE: Patients receive 6-hydroxymethylacylfulvene intravenously for 5 minutes every day for 5 consecutive days. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed after every 2 treatment courses.
PROJECTED ACCRUAL: Approximately 12-37 patients will be accrued for this study within 6-19 months.
Eligibility
Ages Eligible for Study: 18 Years and above
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |